公开(公告)号：US20230339851A1

公开(公告)日：2023-10-26

申请号：US18186265

申请日：2023-03-20

Applicant: CHEMOCENTRYX, INC.

Inventor： Hiufung CHU ,  Pingchen FAN ,  Yandong LI ,  Viengkham MALATHONG ,  Jay POWERS ,  Hiroko TANAKA ,  Yibin ZENG ,  Penglie ZHANG

IPC: C07D231/14 ,  C07D261/18 ,  C07D317/60 ,  C07D237/24 ,  C07D309/10 ,  C07D275/03 ,  C07D319/12 ,  C07D307/24 ,  C07D207/16 ,  C07D309/06 ,  C07D493/08 ,  C07D295/195 ,  C07D239/28 ,  C07D307/16 ,  C07D265/30 ,  C07D309/28 ,  C07D309/08 ,  C07D211/60 ,  C07D207/22 ,  C07D233/90 ,  C07D317/66 ,  C07D211/62 ,  C07D335/02 ,  C07C311/44 ,  C07D307/68 ,  C07D213/81 ,  C07D471/08

CPC classification number: C07C311/44 ,  C07D207/16 ,  C07D207/22 ,  C07D211/60 ,  C07D211/62 ,  C07D213/81 ,  C07D231/14 ,  C07D233/90 ,  C07D237/24 ,  C07D239/28 ,  C07D261/18 ,  C07D265/30 ,  C07D275/03 ,  C07D295/195 ,  C07D307/16 ,  C07D307/24 ,  C07D307/68 ,  C07D309/06 ,  C07D309/08 ,  C07D309/10 ,  C07D309/28 ,  C07D317/60 ,  C07D317/66 ,  C07D319/12 ,  C07D335/02 ,  C07D471/08 ,  C07D493/08 ,  C07C2601/02 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2601/16 ,  C07C2601/18 ,  C07C2602/08 ,  C07C2602/18 ,  C07C2602/42

Abstract: Provided are sulfonamide compounds having formula (I):





or a pharmaceutically acceptable salt thereof, wherein R, R1, R2, R3, R4 and the subscripts n and m have the meanings provided in the specification. The compounds are useful for treating diseases and conditions associated with CXCR6 activity.

公开(公告)号：US20230125684A1

公开(公告)日：2023-04-27

申请号：US17820281

申请日：2022-08-17

Applicant: CHEMOCENTRYX, INC.

Inventor： Penglie ZHANG ,  Daniel R. MARSHALL ,  Howard S. ROTH ,  Aubrie HARLAND

IPC: C07D471/04 ,  C07D471/10 ,  C07D401/14 ,  C07D487/04 ,  C07D413/14 ,  C07D405/14 ,  C07D491/107 ,  C07D513/04 ,  C07D417/14 ,  C07D491/20

Abstract: Compounds of formula (I) are provided which are useful in the treatment of diseases or conditions modulated at least in part by CCR6:

公开(公告)号：US20220280481A1

公开(公告)日：2022-09-08

申请号：US17527939

申请日：2021-11-16

Applicant: CHEMOCENTRYX, INC.

Inventor： James J. CAMPBELL ,  Karen EBSWORTH ,  Antoni KRASINSKI ,  Venkat Reddy MALI ,  Jeffrey McMAHON ,  Rajinder SINGH ,  Ju YANG ,  Chao YU ,  Penglie ZHANG

IPC: A61K31/4035 ,  A61P29/00 ,  A61P17/06

Abstract: The present disclosure provides, inter alia, methods of treating generalized pustular psoriasis (GPP) by administering an effective amount of a Chemokine Receptor 6 (CCR6) antagonist and/or a C-X-C motif chemokine receptor 2 (CXCR2) antagonist. Also provided herein are methods of modulating dysregulated IL-36 signaling in a subject in need thereof and methods of reducing neutrophil, inflammatory dendritic cell (iDC), and/or CD4 T cell accumulation in a subject in need thereof, said methods, include dministering an effective amount of a Chemokine Receptor 6 (CCR6) antagonist and/or a C-X-C motif chemokine receptor 2 (CXCR2) antagonist. In some embodiments, the CCR6 and/or CXCR2 antagonist has the formula:

公开(公告)号：US20210130347A1

公开(公告)日：2021-05-06

申请号：US17071056

申请日：2020-10-15

Applicant: CHEMOCENTRYX, INC.

Inventor： Pingchen FAN ,  Christopher W. LANGE ,  Rebecca M. LUI ,  Darren J. McMURTRIE ,  Ryan J. SCAMP ,  Ju YANG ,  Yibin ZENG ,  Penglie ZHANG

IPC: C07D471/04

Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R2a, R2b, R3, R3a, R4, R6, R7, R8, A, Z, X1 and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

公开(公告)号：US20210130325A1

公开(公告)日：2021-05-06

申请号：US17071077

申请日：2020-10-15

Applicant: CHEMOCENTRYX, INC.

Inventor： Pingchen FAN ,  Christopher W. LANGE ,  Rebecca M. LUI ,  Darren J. McMURTRIE ,  Ryan J. SCAMP ,  Ju YANG ,  Yibin ZENG ,  Penglie ZHANG

IPC: C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D401/12 ,  C07D487/10

Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R2a, R2b, R3, R3a, R4, R6, R7, R8, A, Z, X1 and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

公开(公告)号：US20210093613A1

公开(公告)日：2021-04-01

申请号：US16923197

申请日：2020-07-08

Applicant: CHEMOCENTRYX, INC.

Inventor： Xi CHEN ,  Pingchen FAN ,  Yandong LI ,  Jay P. POWERS ,  Viengkham MALATHONG ,  Sreenivas PUNNA ,  Hiroko TANAKA ,  Penglie ZHANG ,  Dean DRAGOLI

IPC: A61K31/4178 ,  A61K45/06 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D471/04 ,  C07D487/04 ,  A61K31/4155 ,  A61K31/4192 ,  A61K31/4196

Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are diazole lactam derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated disease, and as controls in assays for the identification of competitive CCR1 antagonists.

公开(公告)号：US20200289472A1

公开(公告)日：2020-09-17

申请号：US16742139

申请日：2020-01-14

Applicant: CHEMOCENTRYX, INC.

Inventor： Israel CHARO ,  Heiyoun JUNG ,  Thomas J. SCHALL ,  Penglie ZHANG

IPC: A61K31/4192 ,  C07K16/28 ,  A61P35/00 ,  A61K45/06 ,  A61K9/00 ,  A61K31/4178 ,  A61K31/496 ,  A61K39/395 ,  C07K16/30

Abstract: The present invention provides methods for reducing tumor burden, tumor growth, tumor progression, and/or metastasis in a subject suffering from a solid tumor cancer such as triple negative breast cancer. The methods include administering to a subject in need thereof a therapeutically effective amount of a PD-L1 inhibitor or a PD-1 inhibitor in combination with a small molecule chemokine receptor antagonist that blocks CCR1.

公开(公告)号：US20190144389A1

公开(公告)日：2019-05-16

申请号：US16173914

申请日：2018-10-29

Applicant: CHEMOCENTRYX, INC.

Inventor： Pingchen FAN ,  Rebecca M. LUI ,  Venkat Reddy MALI ,  Rajinder SINGH ,  Yibin ZENG ,  Penglie ZHANG

IPC: C07D211/60 ,  A61K31/451 ,  A61K45/06

Abstract: Compounds are provided to modulate the C5a receptor. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

公开(公告)号：US20180250293A1

公开(公告)日：2018-09-06

申请号：US15820008

申请日：2017-11-21

Applicant: CHEMOCENTRYX, INC.

Inventor： Penglie ZHANG ,  Andrew M.K. PENNELL ,  John J. Kim WRIGHT ,  Wei CHEN ,  Manmohan R. LELETI ,  Yandong LI ,  Lianfa LI ,  Yuan XU ,  Mark M. GLEASON ,  Yibin ZENG ,  Kevin Lloyd GREENMAN

IPC: A61K31/496 ,  A61K45/06 ,  A61K31/5377 ,  C07D471/04 ,  C07D487/04

CPC classification number: A61K31/496 ,  A61K31/5377 ,  A61K45/06 ,  C07D471/04 ,  C07D487/04

Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.

公开(公告)号：US20180086756A1

公开(公告)日：2018-03-29

申请号：US15692811

申请日：2017-08-31

Applicant: CHEMOCENTRYX, INC.

Inventor： Junfa FAN ,  Jaroslaw KALISIAK ,  Rebecca M. LUI ,  Venkat Reddy MALI ,  Jeffrey P. McMAHON ,  Jay P. POWERS ,  Hiroko TANAKA ,  Yibin ZENG ,  Penglie ZHANG

IPC: C07D471/04 ,  A61K31/4725 ,  C07D405/14 ,  A61K31/536 ,  C07D413/14 ,  A61K31/453 ,  C07D405/04 ,  A61K31/4545 ,  A61K31/496

CPC classification number: C07D471/04 ,  A61K31/453 ,  A61K31/4545 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/536 ,  A61K45/06 ,  A61P35/00 ,  A61P37/00 ,  C07D405/04 ,  C07D405/14 ,  C07D413/14

Abstract: Compounds are provided that are modulators of the CCR2 receptor. The compounds have the general formula (I): and are useful in pharmaceutical compositions, methods for the treatment of diseases and disorders involving the pathologic activation of CCR2 receptors.